Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: Results from the POSEIDON and TAC-HFT trials

Stem Cells Translational Medicine

Volumn 6, Issue 5, 2017, Pages 1366-1372

  Ramireddy, Archana ^a   Brodt, Chad R ^a   Mendizabal, Adam M ^b   Difede, Darcy L ^a   Healy, Chris ^a   Goyal, Vishal ^a   Alansari, Yahya ^a   Coffey, James O ^a   Viles Gonzalez, Juan F ^a   Heldman, Alan W ^a   Goldberger, Jeffrey J ^a   Myerburg, Robert J ^a   Hare, Joshua M ^a   Mitrani, Raul D ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EMMES CORPORATION   (United States)

Author keywords

Cardiac arrhythmias; Cardiomyopathy; Heart failure; Stem cells; Ventricular tachycardia

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BONE MARROW DERIVED MONONUCLEAR CELL THERAPY AGENT; CELL THERAPY AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESENCHYMAL STEM CELL THERAPY AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE MARROW DERIVED MONONUCLEAR CELL; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ECTOPIA CORDIS; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART PROARRHYTHMIA; HEART RATE; HEART RATE VARIABILITY; HUMAN; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; NEW YORK HEART ASSOCIATION CLASS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; POST HOC ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSENDOCARDIAL DRUG DELIVERY SYSTEM; AGED; CARDIOMYOPATHY; CYTOLOGY; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; PHYSIOLOGY; STEM CELL;

AGED; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; STEM CELLS; TACHYCARDIA, VENTRICULAR;

EID: 85019421010     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.1002/sctm.16-0328     Document Type: Article

References (31)

1. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787–1847.
2. Heidenreich PA, Albert NM, Allen LA et al. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ Heart Fail 2013;6:606–619.
3. Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114:763–776.
4. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary stem cell transplantation in 191 patients with chronic heARt failure: The STAR-heart study. Eur J Heart Fail 2010;12:721–729.
5. Hare JM, Fishman JE, Gerstenblith G et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. JAMA 2012;308: 2369–2379.
6. Heldman AW, DiFede DL, Fishman JE et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial. JAMA 2014;311:62–73.
7. Karantalis V, DiFede DL, Gerstenblith G et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. Circ Res 2014; 114:1302–1310.
8. Menasche P, Alfieri O, Janssens S et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: First randomized placebo-controlled study of myoblast transplantation. Circulation 2008;117:1189– 1200.
9. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. Circulation 2012;125:1043–1052.
10. Myerburg RJ, Halperin H, Egan DA et al. Pulseless electric activity: Definition, causes, mechanisms, management, and research priorities for the next decade: Report from a National Heart, Lung, and Blood Institute workshop. Circulation 2013;128:2532–2541.
11. Myerburg RJ. Cardiac Arrest and sudden cardiac death. In: Mann DL, Zipes DP, Libby P et al., ed. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 10th edn. Philadelphia, PA: Elsevier Sanders, 2015: 821–860.
12. Mitrani RD, Myerburg RJ. Ten advances defining sudden cardiac death. Trends Cardiovasc Med 2016;26:23–33.
13. Klem I, Weinsaft JW, Bahnson TD et al. Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol 2012;60:408–420.
14. Huikuri HV, Stein PK. Heart rate variability in risk stratification of cardiac patients. Prog Cardiovasc Dis 2013;56:153–159.
15. Chang MG, Tung L, Sekar RB et al. Proarrhythmic potential of mesenchymal stem cell transplantation revealed in an in vitro coculture model. Circulation 2006;113:1832– 1841.
16. Fouts K, Fernandes B, Mal N et al. Electrophysiological consequence of skeletal myoblast transplantation in normal and infarcted canine myocardium. Heart Rhythm 2006;3: 452–461.
17. Fukushima S, Varela-Carver A, Coppen SR et al. Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation 2007; 115:2254–2261.
18. Beeres SL, Zeppenfeld K, Bax JJ et al. Electrophysiological and arrhythmogenic effects of intramyocardial bone marrow cell injection in patients with chronic ischemic heart disease. Heart Rhythm 2007;4:257–265.
19. Huikuri HV, Kervinen K, Niemela M et al. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J 2008;29: 2723–2732.
20. Trachtenberg B, Velazquez DL, Williams AR et al. Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J 2011;161:487–493.
21. Crawford MH, Bernstein SJ, Deedwania PC et al. ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Com-mittee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology. J Am Coll Cardiol. 1999;34:912–948.
22. Patel AN, Henry TD, Quyyumi AA et al. Ixmyelocel-T for patients with ischaemic heart failure: A prospective randomised double-blind trial. Lancet 2016;387:2412–2421.
23. Rosen MR, Myerburg RJ, Francis DP et al. Translating stem cell research to cardiac disease therapies: Pitfalls and prospects for improvement. J Am Coll Cardiol 2014;64:922– 937.
24. Liao SY, Liu Y, Siu CW et al. Proarrhythmic risk of embryonic stem cell-derived cardiomyocyte transplantation in infarcted myocardium. Heart Rhythm 2010;7:1852– 1859.
25. Wang D, Zhang F, Shen W et al. Mesenchymal stem cell injection ameliorates the inducibility of ventricular arrhythmias after myocardial infarction in rats. Int J Cardiol 2011;152:314–320.
26. Menasche P, Hagege AA, Vilquin JT et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003;41:1078– 1083.
27. Siminiak T, Kalawski R, Fiszer D et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: Phase I clinical study with 12 months of follow-up. Am Heart J 2004;148:531–537.
28. Trzos E, Krzeminska-Pakula M, Rechcinski T et al. The effects of intracoronary autologous mononuclear bone marrow cell transplantation on cardiac arrhythmia and heart rate variability. Kardiol Pol 2009;67:713– 721.
29. Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 2004;364:141–148.
30. Hare JM, Traverse JH, Henry TD et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009;54:2277–2286.
31. Mathiasen AB, Qayyum AA, Jorgensen E et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: A randomized placebo-controlled trial (MSC-HF trial). Eur Heart J 2015;36:1744–1753.